Stacey Ducombs
Cardiovascular Disease · New Orleans, LANPI 1033329529
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Medtronic at 26.1% of the total. Reporting peaked in 2021 at $503 and has fallen 95.8% since, to $21 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in LA, where the typical reported total is $3,225.
Across 46 payments — averaging $29.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$353
- Irhythm Technologies, Inc.$217
- Abbott$162
- Impulse Dynamics (USA) Inc.$99
- E.r. Squibb & Sons, L.L.C.$90
- Boston Scientific$56
- plus $374 from 16 others
What the payments were for
- Food & beverage$1,350100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,350 in reported general payments places this provider in the 35th percentile of 281 cardiovascular disease providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $13,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $21 | $13,06019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in New Orleans
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Alexandra SanchezNew Orleans$69K
- Nabeel SaghirNew Orleans$49K
- Aimee HiltboldNew Orleans$29K
- Richard MilaniNew Orleans$28K
- Salima QamruddinNew Orleans$27K
- Joseph EnglertNew Orleans$19K
- Emmett ChapitalNew Orleans$13K
- Yvonne GillilandNew Orleans$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.